Quince Therapeutics Files Pro Forma Financials for Series C Conversion Ahead of Special Meeting
QNCX has more than doubled off its 52-week low of $15.1.
Summary
Quince Therapeutics filed pro forma financials showing the impact of converting Series C Preferred Stock into common stock, which will increase shares outstanding from 1.0 million to 12.0 million and reclassify a $6.3 million warrant liability to equity.
Key Events · Financing and Capital Events · QNCX
-
Pro Forma Conversion Details
The filing shows the conversion of 211,301.868 shares of Series C Preferred Stock into 10,987,728 shares of common stock, increasing shares outstanding from 1,017,063 to 12,004,791.
-
Warrant Liability Reclassification
Upon conversion, a $6.3 million Series C Preferred Stock warrant liability will be reclassified to equity, improving the balance sheet.
-
Potential Cash Settlement Risk
If the company fails to deliver common stock upon conversion after six months, holders may require cash settlement at fair value, creating a potential liquidity risk.
-
Special Meeting Pending
The conversion is contingent on stockholder approval at a special meeting, with the preliminary proxy filed on July 31, 2026.
Analysis · QNCX · Life Sciences
The filing provides the first detailed pro forma financials for the conversion of Series C Preferred Stock into common stock, a key step in the Orphai acquisition financing. It quantifies the massive dilution: 10,987,728 new shares will be issued, increasing the share count from 1,017,063 to 12,004,791 — an increase of over 10x. The conversion also reclassifies a $6.3 million warrant liability to equity, improving the balance sheet. However, the filing also highlights a potential cash settlement obligation if the company fails to deliver shares upon conversion, adding risk. This is material information for shareholders ahead of the special meeting vote.
At the time of this filing, QNCX was trading at $34.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.6M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.